GSK4527226 (AL101) for Early Alzheimer's Disease (NCT06079190)

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Overview

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Overview

A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease

This Phase 2 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the investigational approach["@novel2024"].

Alzheimers Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options["@alzheimers2023"].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06079190 |
| Phase | PHASE2 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | GlaxoSmithKline |
| Enrollment | 367 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Start Date | 2023-10-20 00:00:00 |
| Completion Date | 2026-11-23 00:00:00 |
| Last Updated | 2025-11-14 00:00:00 |

Conditions Studied

• Alzheimer's Disease

Scientific Background

Disease Context

Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].

The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[@amyloid2023].

Therapeutic Mechanism

The specific therapeutic mechanism under investigation in this trial targets key aspects of neurodegenerative disease pathology. Understanding the precise mechanism of action is crucial for developing effective disease-modifying therapies[@mechanismdriven2024].

Study Design

This is a Phase 2, randomized, double-blind, placebo-controlled clinical trial. Phase 2 trials build upon Phase 1 safety data to evaluate efficacy and identify optimal dosing regimens[@clinical2023].

Phase 2 studies typically:

• Evaluate multiple dose levels
• Assess preliminary efficacy signals
• Further characterize safety and tolerability
• Inform Phase 3 trial design

Outcome Measures

Primary Endpoints

• Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76

Participating Sites

The trial is being conducted at multiple centers worldwide, including:

• San Diego, California, United States
• Lake Mary, Florida, United States
• Lake Worth, Florida, United States
• Maitland, Florida, United States
• Miami, Florida, United States

Clinical Significance

This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may:

The rigorous design of this clinical trial ensures that any demonstrated efficacy will be supported by robust evidence, potentially accelerating the path to regulatory approval and patient access[@future2024].

GSK4527226 (AL101): GSK's Novel Therapeutic Candidate

Background and Development

GSK4527226, also known as AL101, is a novel therapeutic agent developed by GlaxoSmithKline (GSK) for the treatment of Alzheimer's disease. This compound represents GSK's entry into the Alzheimer's disease therapeutic pipeline, joining other pharmaceutical companies in the race to develop disease-modifying treatments for this devastating condition.

GSK's decision to develop AL101 reflects:

• Growing understanding of AD pathophysiology beyond amyloid
• Recognition of the need for earlier intervention
• Leveraging of GSK's expertise in small molecule development

Target and Mechanism

While the specific molecular target of GSK4527226 is proprietary, based on the trial design and GSK's pipeline, several possibilities are under investigation:

Amyloid-Targeting Mechanisms:

Non-Amyloid Mechanisms:

The Phase 2 trial design with 3 dose arms suggests:

• Dose-response evaluation
• Multiple dosing regimens being tested
• Optimization of therapeutic window

Rationale for Early Alzheimer's Disease

This trial specifically targets early Alzheimer's disease, reflecting the field's shift toward earlier intervention:

Benefits of Early Treatment:

Early AD Definition:

• Mild Cognitive Impairment (MCI) due to AD: Pre-dementia stage with objective cognitive impairment
• Mild AD Dementia: Early stage with measurable cognitive deficits
• Biomarker Confirmed: Amyloid and/or tau positivity required

Biomarker Strategy

The trial incorporates biomarker assessments to:

Key biomarkers being measured:

• Amyloid PET: Quantify amyloid plaque burden
• Tau PET: Monitor neurofibrillary tangle accumulation
• CSF Biomarkers: Aβ42, total tau, phosphorylated tau
• Neurodegeneration: MRI volume measures, FDG PET metabolism

Comparison to Other Anti-Amyloid Therapies

Monoclonal Antibodies

The amyloid-targeting monoclonal antibody field has produced the first disease-modifying AD drugs:

| Antibody | Company | Mechanism | Approval Status |
|----------|---------|-----------|-----------------|
| Lecanemab | Biogen/Eisai | Aβ protofibril binding | Approved (2023) |
| Donanemab | Eli Lilly | N-terminal Aβ plaque binding | Approved (2024) |
| Gantenerumab | Roche | Full-length Aβ plaques | Withdrawn |
| Crenezumab | Genentech | Aβ oligomers | Discontinued |

These antibodies all demonstrated:

• Amyloid plaque reduction (dose-dependent)
• Slowed cognitive decline (modest effect sizes)
• ARIA-E (brain edema) as main safety signal

Small Molecule Approaches

Small molecule BACE inhibitors faced challenges:

| Drug | Company | Status | Issue |
|-----|---------|--------|-------|
| Verubecestat | Merck | Discontinued | Negative cognition, liver toxicity |
| Lanabecestat | AstraZeneca | Discontinued | Liver toxicity |
| Elenbecestat | Eisai | Discontinued | Liver enzyme elevation |

GSK4527226's advantages may include:

• Novel mechanism beyond BACE
• Better safety profile
• Oral bioavailability (vs. IV infusions for antibodies)

Pipeline Comparison

Other Phase 2 AD drugs in development:

| Drug | Company | Mechanism | Trial |
|------|---------|-----------|-------|
| GV-971 | Shanghai Green Valley | Oligosaccharide | Approved China |
| Blarcamesine | Anavex | Sigma-1 agonist | Phase 2/3 |
| AL101 | GSK | TBD | Phase 2 (this trial) |

Study Design Deep Dive

Three-Arm Design

The trial uses a 3-arm parallel group design:

Randomization (1:1:1)
|
+--------------------+--------------------+
| | |
Placebo (n~122) Low Dose (n~122) High Dose (n~122)
| | |
| | |
52 weeks 52 weeks 52 weeks
| | |
+--------------------+--------------------+
|
Assessment: CDR-SB at weeks 52, 64, 76

Design Rationale:

• Three arms allow curved dose-response assessment
• Placebo control enables clear efficacy demonstration
• Multiple timepoints capture trajectory changes

Primary Endpoint: CDR-SB

The Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) is the primary endpoint:

CDR-SB Components:

• Memory (0-3)
• Orientation (0-3)
• Judgment and problem-solving (0-3)
• Community affairs (0-3)
• Home and hobbies (0-3)
• Personal care (0-3)

Clinical Meaningfulness:

• 1 point = detectable meaningful change
• 0.5-1.0 points = commonly cited MCID
• Amyloid antibodies: 1.8 (lecanemab), 2.3 (donanemab)

Secondary Endpoints

Safety Assessments

Comprehensive safety monitoring:

• Adverse event collection (all causalities)
• Laboratory parameters (hematology, chemistry)
• Vital signs and ECGs
• Brain MRI (ARIA monitoring if applicable)
• Physical examinations

Clinical and Regulatory Implications

If Positive

A successful Phase 2 trial would:

Current AD Treatment Landscape

AD treatment has evolved significantly:

| Treatment | Type | Effect |
|-----------|------|--------|
| Cholinesterase inhibitors | Symptomatic | Moderate cognitive benefit |
| Memantine | Symptomatic | Modest benefit in moderate-severe AD |
| Lecanemab | Disease-modifying | 27% slowed decline |
| Donanemab | Disease-modifying | 35% slowed decline |

GSK4527226, if approved, would enter a market with:

• Growing acceptance of disease modification
• Need for alternative mechanisms
• Potential for combination approaches

Competitive Position

GSK's entry into AD therapeutics reflects:

Related Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Early Alzheimer's Disease](/diseases/early-alzheimers-disease)
• [Amyloid-Targeting Therapies](/therapeutics/amyloid-targeting)
• [BACE Inhibitors](/therapeutics/bace-inhibitors)
• [Disease-Modifying Therapies](/therapeutics/disease-modifying)
• [Clinical Trials Overview](/clinical-trials/overview)
• [Drug Development Pipeline](/clinical-trials/drug-pipeline)
• [GlaxoSmithKline](/companies/glaxo-smith-kline)
• [CDR-SB Endpoint](/biomarkers/cdr-sb)

References